SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Tagraxofusp (Primary)
- Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Stemline Therapeutics
- 13 Dec 2022 Results (n=65) of sub-group analysis assessing safety and efficacy of tagraxofusp in first-line patients who had blastic plasmacytoid dendritic cell neoplasm, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 01 Oct 2022 Results of sub analysis(n=65) assessing Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm by Age and Baseline Disease Involvement((skin-only, systemic-only, and skin+systemic) published in the Clinical Lymphoma, Myeloma & Leukemia.
- 01 Oct 2022 Results of an integrated analysis assessing aggregated safety data for Tagraxofusp monotherapy from three clinical trials: Study 0114, Study 0214 and Study 0314 published in the Clinical Lymphoma, Myeloma & Leukemia